Funding for this research was provided by:
National Basic Research Program of China (973 Program) (2018YFC1004203, 2018YFC1003703)
National Natural Science Foundation of China (81501797)
Text and Data Mining valid from 2019-10-10
Received: 9 May 2019
Accepted: 2 September 2019
First Online: 10 October 2019
Ethics approval and consent to participate
: Not applicable.
: Not Applicable.
: The authors declare the following competing financial interest(s): P.R.T. founded Padlock Therapeutics and is entitled to payments from Bristol Myers Squibb if certain milestones are met. P.R.T. is a consultant for Celgene and Disarm Therapeutics. P.R.T. holds a patent on Cl-amidine. Other authors have no financial conflict of interest to disclose.